BioSpace News Archive

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet need, today reported financial results for its fiscal year ended March 31, 2020.

iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the company has been added to the Russell 2000® Index and the Russell 3000® Index at the conclusion of this year’s reconstitution of the Russell stock indexes, effective upon the opening of the U.S. stock markets today, Monday, June 29, 2020. “We are pleased to be included in the Russell 2000® Inde

Tufts Health Plan Foundation board approved an additional $900,000 to support recovery and rebuilding efforts addressing the effects of the coronavirus pandemic in Massachusetts, Rhode Island, New Hampshire and Connecticut.

Identifies “Triglyceride Normalization” phenomenon prior to patient randomization and treatment as likely contributor to unusually high placebo effect in TRILOGY 1 Acasti management to host conference call at 1 PM ET today LAVAL, Quebec, June 29, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre ® (omega

ABEC acknowledged as a model for exemplary worksite safety and health programs among industry peers

Phesgo offers faster administration of Perjeta and Herceptin under the skin in just minutes, compared to hours with standard intravenous administration — — Data showed that 85% of patients preferred Phesgo compared to standard intravenous administration —

Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage, regenerative medicine company creating the next generation of differentiated products to improve outcomes in patients undergoing surgery, announced today the launch of its newest OsteGro® family product, OsteGro V,

Accel Clinical Services (ACS), the parent company of Accel Research Sites, is excited to announce its acquisition of the assets of AMPLIFY Clinical.

Individuals Encouraged to Make an Appointment to Get a Free, Confidential Memory Screening Through Secure Video Conference

Synergy CHC Corp. (OTCQB: SNYR) (“Synergy” or the “Company”), a consumer health care & beauty company, today reported results for the quarter ended March 31, 2020.